



ICVRD-2024

2nd International Conference on

**Vaccine Research and
Development**

**April 22-23,
2024**

**Munich,
Germany**

Chair

De-Chu Christopher Tang, CEO of VaxDome, USA

Co - Chair

Chil-Yong Kang, The University of Western Ontario, Canada

09:00 - 09:30

On Spot Registrations

Plenary Presentations

09:30 - 10:10

P **Title:** Virus/Mutation-Agnostic Vaccines

De-Chu Christopher Tang, CEO of VaxDome, USA

10:10 - 10:50

P **Title:** Research and Development of Vaccines for Future Pandemic Preparedness

Chil-Yong Kang, The University of Western Ontario, Canada

10:50 - 11:05

Refreshment Break

11:05 - 11:45

P **Title:** The Power of Cultural Validation in Immunization Equity

Julissa Soto, CEO and Founder of Julissa Soto Latino Health Equity Consulting, USA

11:45 - 12:25

P **Title:** The Perils & Pitfalls of Vaccine Safety Monitoring

Graeme Ladds, Director of PharSafer, United Kingdom

12:25 - 13:05

P **Title:** A Novel Pd1-Enhanced DNA Vaccine for Therapeutic Use in People Living with HIV-1 Infection

Xia JIN, CEO of Immuno Cure, Hong Kong

13:05 - 14:05

Group Photo

Lunch Break

14:05 - 14:45

P **Title:** Viral Gene Drive Spread During Herpes Simplex Virus 1 Infection in Mice

Keith R Jerome, University of Washington, USA

14:45 - 15:25

P **Title:** Controlling Chronic Viral Infections Where Lesions are Mainly Caused by the Host Response

Barry T Rouse, University of Tennessee, USA

Keynote Presentations

15:25 - 16:00

Κ **Title:** Turkovac: Interim Results of Phase 1 and 2 Trials for a Safe and Effective Covid-19 Vaccine

Aykut Ozdarendeli, Erciyes University, Turkey

16:00 - 16:35

Κ **Title:** From Research to Resilience: A Strategic Pipeline for mAb and Vaccine Development in Africa

Tsepo Tsekoa, Council for Scientific & Industrial Research, South Africa

16:35 - 16:50

Refreshment Break

16:50 - 17:25

Κ **Title:** Digital Innovations Optimized to Achieve Vaccine Last-Mile Quality Control in Nigeria

Atef Fawaz, eHealth Africa, Nigeria

17:25 - 18:00

Κ **Title:** Personalized and Precision Medicine (Ppm) as a Unique Healthcare Model to be Set up Via Biodesign-Driven Biotech and Upgraded Biomarketing to Secure the Human Healthcare and Biosafety

Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Sciences, Russia

Poster

Title: Obtaining the Subunit Vaccine Candidate S. Aureus Enterotoxin B (Seb) Protein via Conventional Methods

Hivda Ulbegi Polat, Tubitak Marmara Research Center, Turkey

End of the Day 1 Conference

Chair

De-Chu Christopher Tang, CEO of VaxDome, USA

Co-Chair

Chil-Yong Kang, The University of Western Ontario, Canada

09:00 - 09:30

On Spot Registrations

Plenary Presentations

09:30 - 10:10

P **Title:** mRNA Vaccine Research and Development for Sustainability: Process and Product Innovation Partnerships of the mRNA Technology Development and Transfer Programme
Ike James, Medicines Patent Pool, Switzerland

10:10 - 10:50

P **Title:** Immunization of Patients with Autoimmune Rheumatic Disease Against Influenza: A Study of Vaccine Safety and Immunogenicity
Lyudmila Stojanovich, Belgrade University, Serbia

10:50 - 11:05

Refreshment Break

Keynote Presentations

11:05 - 11:40

K **Title:** Translating Veterinary Medicines from Development to Scale: A Case Study for Plant Produced Vaccine Candidate Against Bluetongue Disease
Nobalanda Mokoena, Onderstepoort Biological Products, South Africa

11:40-12:15

K **Title:** Next Generation mRNA Vaccines for Aquaculture and Agriculture
Essa Suleman, Council for Scientific & Industrial Research, South Africa

Invited Presentations

12:15 - 12:35

I **Title:** Monitoring Memory B Cells by Next Generation Immunospot® Provides Insights into Humoral Immunity that Measurements of Circulating Antibodies Do Not Reveal
Greg A. Kirchenbaum, Cellular Technology Limited, USA

12:35 - 12:55

I **Title:** Development of Epitope-Based Diva Vaccines for Senecavirus A
Fandan Meng, Harbin Veterinary Research Institute, China

12:55 - 13:15

I **Title:** Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Decreases Recombination Frequency and Pathogenicity
Tongqing An, Harbin Veterinary Research Institute, China

Exhibitors Details

Description:

CTL is the only company that specializes on GLP compliant high throughput ELISPOT analysis for monitoring T cell immunity in clinical trials (CRO). CTL is the leading manufacturer of ELISPOT analyzers, reagents required for ELISPOT standardization, including reference PBMCs, up to 4 color ImmunoSpot® ELISPOT T and B Cell Kits and Serum-Free-Media.



UPCOMING CONFERENCE



**3rd International Conference on
Vaccine Research and
Development**

May 26-28, 2025 | Amsterdam, Netherlands